To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected]
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2023 financial results approved by the Board of Directors on March 26, 2024.
Karine LIGNEL, Deputy Managing Director and COO of Oncodesign Precision Medicine declares: “With a cash position of 10 million euros at the end of 2023, to which have since been added the proceeds of the fundraising of 2 million euros, and the receipt of 0.5 million euros for the subsidy and the recoverable advance within the framework of the ANIMUS (Deep Tech) program, OPM benefits from solid financial visibility until the beginning of 2025 for the development of its programs. We have also received agreement for an FEDER program and are awaiting the formalization of an agreement within the framework of i-DEMO, for a total amount of public funding which could reach nearly 8 million euros over the duration of the projects. »